C172H265N43O51
3751 g/mol
원료의약품경고
Liraglutide
CAS204656-20-2
용도 분류
원료의약품
화합물 분류
펩타이드
주요 용도
의약 원료
Liraglutide is a pharmaceutical raw material used in the manufacturing of anti-diabetic medications. It is a synthetic peptide compound consisting of 33 amino acids with a fatty acid side chain, designed for use in research and production of treatments targeting type 2 diabetes and obesity.
active pharmaceutical ingredient for anti-diabetic formulationsresearch compound for metabolic disease studies
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 204656-20-2
관련 화합물
강한 관련구조 유사유사도 0.87
Glucagon-like peptide 1 (1-37)
CAS87805-34-3
active pharmaceutical ingredient
유사구조 유사유사도 0.84
세마글루타이드
CAS910463-68-2
active pharmaceutical ingredient
유사구조 유사유사도 0.84
GLP-1 (1-36) amide (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 trifluoroacetate salt
CAS99658-04-5
active pharmaceutical ingredient
유사구조 유사유사도 0.76
Teduglutide
CAS197922-42-2
active pharmaceutical ingredient
참고동일 카테고리
Valerianol
CAS20489-45-6
plant metabolite reference standard
참고동일 카테고리
(R,R)-Epoxy Leucine Carfilzomib
CAS2049025-76-3
proteasome inhibitor impurity reference standard
참고동일 카테고리
Quinapyramine
CAS20493-41-8
veterinary trypanocidal agent
참고동일 카테고리
Upadacitinib hemihydrate
CAS2050057-56-0
active pharmaceutical ingredient
안전 참조
경고
H351Suspected of causing cancer
H361Suspected of damaging fertility or the unborn child
식별자
IUPAC 이름
(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
InChIKey
YSDQQAXHVYUZIW-QCIJIYAXSA-N
SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
동의어 목록 (19)
- Liraglutida [INN-Spanish]
- Liraglutidum [INN-Latin]
- Liraglutida
- Liraglutide
- Liraglutide (rDNA origin)
- Liraglutide recombinant
- Liraglutidum
- NNC 90-1170
- Saxenda
- victoza